RenovoRx, Inc.(RNXT)

Biotechnology · Mountain View, CA

$1.42-0.05 (-3.40%)

Delayed quote: Oct 6, 2026, 1:30 PM EDT

PE Ratio: N/A

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T17:33:57.893Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:33:57.893Z.

Quote observation: 2026-10-06T17:30:03.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 1.42
Unrounded diluted TTM EPS · period ending 2026-06-30: -0.3163

FMP input reference: f2bd7b982a7c38b7b5dde5784864fe9761ce9be9b841b4296251164aedb1f89c

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

RNXT PE Ratio Metrics

PE RATIO

N/A

RNXT Competitors' PE Ratio

RNXT

RenovoRx, Inc.

Current

Market Cap

$63.97M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

GOSS

Gossamer Bio, Inc.

vs RNXT

Market Cap

$64.99M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HRTX

Heron Therapeutics, Inc.

vs RNXT

Market Cap

$64.37M

PE Ratio

N/A

TTM Avg

2.96

3Y Avg

2.96

5Y Avg

2.96

CING

Cingulate Inc.

vs RNXT

Market Cap

$65.46M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ALPS

Alps Group Inc

vs RNXT

Market Cap

$64.06M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLRX

Pliant Therapeutics, Inc.

vs RNXT

Market Cap

$63.16M

PE Ratio

N/A

TTM Avg

45.99

3Y Avg

45.99

5Y Avg

45.99

INCR

InterCure Ltd.

vs RNXT

Market Cap

$65.15M

PE Ratio

N/A

TTM Avg

14.25

3Y Avg

33.42

5Y Avg

30.04

XBIT

XBiotech Inc.

vs RNXT

Market Cap

$66.46M

PE Ratio

N/A

TTM Avg

0.90

3Y Avg

0.90

5Y Avg

0.90

KLRS

Kalaris Therapeutics Inc

vs RNXT

Market Cap

$61.17M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

XLO

Xilio Therapeutics, Inc.

vs RNXT

Market Cap

$61.35M

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
RenovoRx, Inc. (RNXT)	$63.97M	N/A	N/A	N/A	N/A
Gossamer Bio, Inc. (GOSS)vs ›	$64.99M	N/A	N/A	N/A	N/A
Heron Therapeutics, Inc. (HRTX)vs ›	$64.37M	N/A	2.96	2.96	2.96
Cingulate Inc. (CING)vs ›	$65.46M	N/A	N/A	N/A	N/A
Alps Group Inc (ALPS)vs ›	$64.06M	N/A	N/A	N/A	N/A
Pliant Therapeutics, Inc. (PLRX)vs ›	$63.16M	N/A	45.99	45.99	45.99
InterCure Ltd. (INCR)vs ›	$65.15M	N/A	14.25	33.42	30.04
XBiotech Inc. (XBIT)vs ›	$66.46M	N/A	0.90	0.90	0.90
Kalaris Therapeutics Inc (KLRS)vs ›	$61.17M	N/A	N/A	N/A	N/A
Xilio Therapeutics, Inc. (XLO)vs ›	$61.35M	N/A	N/A	N/A	N/A

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$1.42

Forward EPS (Est.)

$-0.26

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

RNXT PE Ratio Metrics

RNXT Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics